SG11202012451WA - Pcsk9 antagonist compounds - Google Patents
Pcsk9 antagonist compoundsInfo
- Publication number
- SG11202012451WA SG11202012451WA SG11202012451WA SG11202012451WA SG11202012451WA SG 11202012451W A SG11202012451W A SG 11202012451WA SG 11202012451W A SG11202012451W A SG 11202012451WA SG 11202012451W A SG11202012451W A SG 11202012451WA SG 11202012451W A SG11202012451W A SG 11202012451WA
- Authority
- SG
- Singapore
- Prior art keywords
- antagonist compounds
- pcsk9 antagonist
- pcsk9
- compounds
- antagonist
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6454—Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21061—Kexin (3.4.21.61), i.e. proprotein convertase subtilisin/kexin type 9
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862687913P | 2018-06-21 | 2018-06-21 | |
| PCT/US2019/038155 WO2019246349A1 (en) | 2018-06-21 | 2019-06-20 | Pcsk9 antagonist compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202012451WA true SG11202012451WA (en) | 2021-01-28 |
Family
ID=67263083
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202012451WA SG11202012451WA (en) | 2018-06-21 | 2019-06-20 | Pcsk9 antagonist compounds |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US11427616B2 (en) |
| EP (1) | EP3810626A1 (en) |
| JP (2) | JP7112531B2 (en) |
| KR (1) | KR20210024035A (en) |
| CN (1) | CN112313243A (en) |
| AR (1) | AR115597A1 (en) |
| AU (2) | AU2019290163C1 (en) |
| BR (1) | BR112020025274A8 (en) |
| CA (1) | CA3102629A1 (en) |
| CL (2) | CL2020003257A1 (en) |
| CO (1) | CO2021000456A2 (en) |
| CR (1) | CR20210031A (en) |
| DO (1) | DOP2020000250A (en) |
| EA (1) | EA202190086A1 (en) |
| EC (1) | ECSP21003643A (en) |
| GE (1) | GEP20237506B (en) |
| IL (1) | IL279363A (en) |
| JO (1) | JOP20190150A1 (en) |
| MA (1) | MA52967A (en) |
| MX (1) | MX2020013726A (en) |
| NI (1) | NI202000101A (en) |
| PE (1) | PE20211584A1 (en) |
| PH (1) | PH12020552187A1 (en) |
| SG (1) | SG11202012451WA (en) |
| WO (1) | WO2019246349A1 (en) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100558932B1 (en) * | 2005-04-21 | 2006-03-10 | 주식회사 엠제이스마트 테크놀러지 | Manufacturing method of a ceramic membrane and ceramic membrane that is made by it membrane |
| SG11201507226YA (en) | 2013-03-15 | 2015-10-29 | Protagonist Therapeutics Inc | Hepcidin analogues and uses therof |
| SG11201609614QA (en) | 2014-05-16 | 2016-12-29 | Protagonist Therapeutics Inc | α4β7 INTEGRIN THIOETHER PEPTIDE ANTAGONISTS |
| BR112017001010A2 (en) | 2014-07-17 | 2017-11-14 | Protagonist Therapeutics Inc | oral interleukin-23 receptor peptide inhibitors and their use to treat inflammatory bowel diseases |
| WO2019157268A1 (en) | 2018-02-08 | 2019-08-15 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| WO2019246405A1 (en) | 2018-06-21 | 2019-12-26 | Merck Sharp & Dohme Corp. | Cyclic polypeptides for pcsk9 inhibition |
| WO2019246352A1 (en) | 2018-06-21 | 2019-12-26 | Merck Sharp & Dohme Corp. | Pcsk9 antagonist bicyclo-compounds |
| US11814444B2 (en) | 2018-06-21 | 2023-11-14 | Ra Pharmaceuticals, Inc. | Cyclic polypeptides for PCSK9 inhibition |
| JOP20190150A1 (en) | 2018-06-21 | 2019-12-21 | Merck Sharp & Dohme | Pcsk9 antagonist compounds |
| US11814445B2 (en) | 2018-06-21 | 2023-11-14 | Ra Pharmaceuticals, Inc. | Cyclic polypeptides for PCSK9 inhibition |
| EP3810178A4 (en) | 2018-06-21 | 2022-05-04 | Merck Sharp & Dohme Corp. | Cyclic polypeptides for pcsk9 inhibition |
| WO2021041770A1 (en) * | 2019-08-30 | 2021-03-04 | Merck Sharp & Dohme Corp. | Pcsk9 antagonist compounds |
| EP4076492A4 (en) * | 2019-12-20 | 2024-01-17 | Merck Sharp & Dohme Llc | Pcsk9 antagonist compounds |
| MX2022008741A (en) | 2020-01-15 | 2022-10-03 | Janssen Biotech Inc | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases. |
| US11939361B2 (en) | 2020-11-20 | 2024-03-26 | Janssen Pharmaceutica Nv | Compositions of peptide inhibitors of Interleukin-23 receptor |
| US11932705B2 (en) | 2020-12-18 | 2024-03-19 | Merck Sharp & Dohme Llc | Cyclic polypeptides for PCSK9 inhibition |
| IL310851A (en) * | 2021-08-19 | 2024-04-01 | Merck Sharp & Dohme Llc | Compounds for treating conditions related to pcsk9 activity |
| TW202404574A (en) | 2022-06-15 | 2024-02-01 | 美商默沙東有限責任公司 | Cyclic peptides for trapping interleukin-1 beta |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4393046A (en) | 1981-01-30 | 1983-07-12 | Merck & Co., Inc. | Combination of thiopeptin and other related sulfur-containing cyclic polypeptide antibiotics with rumen-active diimides to improve ruminant feed efficiency |
| DE3841520A1 (en) | 1988-12-09 | 1990-06-13 | Hoechst Ag | ENZYME-INFRINGING DERIVATIVES OF DIPEPTIDES, METHOD FOR THE PRODUCTION THEREOF, METHODS CONTAINING THEM AND THEIR USE |
| US5104869A (en) | 1989-10-11 | 1992-04-14 | American Cyanamid Company | Renin inhibitors |
| US5114937A (en) | 1989-11-28 | 1992-05-19 | Warner-Lambert Company | Renin inhibiting nonpeptides |
| US5095119A (en) | 1990-03-08 | 1992-03-10 | American Home Products Corporation | Renin inhibitors |
| AU6691798A (en) | 1997-03-07 | 1998-09-22 | Metabasis Therapeutics, Inc. | Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase |
| AU6691498A (en) | 1997-03-07 | 1998-09-22 | Metabasis Therapeutics, Inc. | Novel benzimidazole inhibitors of fructose-1,6-bisphosphatase |
| WO1998039344A1 (en) | 1997-03-07 | 1998-09-11 | Metabasis Therapeutics, Inc. | Novel purine inhibitors of fructose-1,6-bisphosphatase |
| KR100818845B1 (en) | 1998-09-09 | 2008-04-01 | 메타베이시스 테라퓨틱스, 인크. | Novel Heteroaromatic Inhibitors of Fructose 1,6-Bisphosphatase |
| WO2002008188A1 (en) | 2000-07-25 | 2002-01-31 | Merck & Co., Inc. | N-substituted indoles useful in the treatment of diabetes |
| US6852738B2 (en) | 2001-01-30 | 2005-02-08 | Merck & Co., Inc. | Acyl sulfamides for treatment of obesity, diabetes and lipid disorders |
| AR040241A1 (en) | 2002-06-10 | 2005-03-23 | Merck & Co Inc | INHIBITORS OF 11-BETA-HYDROXIESTEROID DEHYDROGRENASE 1 FOR THE TREATMENT OF DIABETES OBESITY AND DISLIPIDEMIA |
| JP4340232B2 (en) | 2002-08-29 | 2009-10-07 | メルク エンド カムパニー インコーポレーテッド | Indoles having anti-diabetic activity |
| BR0313825A (en) | 2002-08-29 | 2005-07-12 | Merck & Co Inc | Compound, pharmaceutical composition, method for treating type 2 diabetes mellitus in a mammal, and, compound use |
| JP2007504285A (en) | 2003-01-17 | 2007-03-01 | メルク エンド カムパニー インコーポレーテッド | N-cyclohexylaminocarbonylbenzenesulfonamide derivative |
| CN101636179B (en) | 2006-11-07 | 2012-10-10 | 默沙东公司 | Antagonists of pcsk9 |
| CA2691010A1 (en) | 2007-06-28 | 2008-12-31 | Merck Frosst Canada Ltd. | Substituted fused pyrimidines as antagonists of gpr105 activity |
| WO2009001836A1 (en) | 2007-06-28 | 2008-12-31 | Semiconductor Energy Laboratory Co., Ltd. | Manufacturing method of semiconductor device |
| WO2009042053A2 (en) | 2007-09-21 | 2009-04-02 | Merck & Co., Inc. | Neuromedin u receptor agonists and uses thereof |
| UY32690A (en) | 2009-06-08 | 2011-01-31 | Astrazeneca Ab | SPECIFIC PEPTIDES FOR MELANOCORTIN RECEPTORS |
| WO2011037791A1 (en) | 2009-09-25 | 2011-03-31 | Merck Sharp & Dohme Corp. | Antagonists of pcsk9 |
| CA2813049A1 (en) | 2010-09-23 | 2012-03-29 | The Trustees Of The University Of Pennsylvania | Modified compstatin with improved stability and binding properties |
| NZ612544A (en) | 2010-12-28 | 2015-04-24 | Cadila Healthcare Ltd | Heterocyclic compounds suitable for the treatment of dyslipidemia |
| EP2721063A4 (en) * | 2011-06-20 | 2015-01-14 | Hoffmann La Roche | Pcsk9-binding polypeptides and methods of use |
| PE20181541A1 (en) | 2011-10-27 | 2018-09-26 | Massachusetts Inst Technology | DERIVATIVES OF AMINO ACIDS FUNCTIONALIZED IN THE N TERMINAL, CAPABLE OF FORMING DRUG ENCAPSULATING MICROSPHERES |
| US9534018B2 (en) | 2012-03-13 | 2017-01-03 | Tensive Controls Inc. | Melanocortin analogs having enhanced activity and transport |
| EP2850095B1 (en) | 2012-05-17 | 2019-10-09 | RA Pharmaceuticals, Inc. | Peptide and peptidomimetic inhibitors |
| WO2014140210A1 (en) * | 2013-03-14 | 2014-09-18 | Pieris Ag | Novel binding proteins for pcsk9 |
| CN105228616B (en) | 2013-03-15 | 2019-05-03 | 实发生物医学公司 | Anti- 9 type of proprotein convertase subtilisin Kexin (anti-PCSK9) compound and its method for treating and/or preventing cardiovascular disease |
| US10557129B2 (en) | 2015-01-30 | 2020-02-11 | Pronasci Inc. | Peptides derived from human PCSK9 catalytic domain and uses thereof for promoting LDL-R activity |
| WO2017181061A1 (en) | 2016-04-15 | 2017-10-19 | Ra Pharmaceuticals, Inc. | Ras binding peptides and methods of use |
| BR112018076242A2 (en) | 2016-06-24 | 2019-03-26 | Hoffmann La Roche | pcsk9 inhibitors, inhibited pcsk9, pharmaceutical composition, methods to modulate pcsk9 activity, to inhibit binding of pcsk9 to ldlr, to increase ldlr availability, to reduce ldl-c level, to reduce serum ldl level -c, for the treatment of a cholesterol-related disorder, methods for treating a disorder associated with an abnormal level of ldl-c, a condition associated with a high level of ldl-c, dyslipidemia, hypercholesterolemia, uses of a pcsk9 inhibitor and method for identifying a candidate compound as a pcsk9 inhibitor that binds an epitope of seq id # 1 |
| US10577357B2 (en) | 2016-09-19 | 2020-03-03 | The Texas A&M University System | Inhibitors of LDLR-PCSK9 protein-protein interaction and methods of their use |
| CN107158002B (en) * | 2017-07-01 | 2020-06-16 | 维亚生物科技(上海)有限公司 | Application of benzylene barbiturates as PCSK9 antagonist and in lowering low-density lipoprotein |
| EP3810178A4 (en) | 2018-06-21 | 2022-05-04 | Merck Sharp & Dohme Corp. | Cyclic polypeptides for pcsk9 inhibition |
| US11814445B2 (en) | 2018-06-21 | 2023-11-14 | Ra Pharmaceuticals, Inc. | Cyclic polypeptides for PCSK9 inhibition |
| JOP20190150A1 (en) * | 2018-06-21 | 2019-12-21 | Merck Sharp & Dohme | Pcsk9 antagonist compounds |
| WO2019246405A1 (en) | 2018-06-21 | 2019-12-26 | Merck Sharp & Dohme Corp. | Cyclic polypeptides for pcsk9 inhibition |
| US11814444B2 (en) | 2018-06-21 | 2023-11-14 | Ra Pharmaceuticals, Inc. | Cyclic polypeptides for PCSK9 inhibition |
| WO2019246352A1 (en) | 2018-06-21 | 2019-12-26 | Merck Sharp & Dohme Corp. | Pcsk9 antagonist bicyclo-compounds |
| WO2021041770A1 (en) | 2019-08-30 | 2021-03-04 | Merck Sharp & Dohme Corp. | Pcsk9 antagonist compounds |
-
2018
- 2018-06-21 JO JOP/2019/0150A patent/JOP20190150A1/en unknown
-
2019
- 2019-06-20 EP EP19739801.9A patent/EP3810626A1/en active Pending
- 2019-06-20 PE PE2020002109A patent/PE20211584A1/en unknown
- 2019-06-20 CA CA3102629A patent/CA3102629A1/en active Pending
- 2019-06-20 KR KR1020217001723A patent/KR20210024035A/en active Search and Examination
- 2019-06-20 GE GEAP201915540A patent/GEP20237506B/en unknown
- 2019-06-20 MA MA052967A patent/MA52967A/en unknown
- 2019-06-20 US US16/446,940 patent/US11427616B2/en active Active
- 2019-06-20 CR CR20210031A patent/CR20210031A/en unknown
- 2019-06-20 CN CN201980041438.5A patent/CN112313243A/en active Pending
- 2019-06-20 JP JP2020570427A patent/JP7112531B2/en active Active
- 2019-06-20 SG SG11202012451WA patent/SG11202012451WA/en unknown
- 2019-06-20 AU AU2019290163A patent/AU2019290163C1/en active Active
- 2019-06-20 BR BR112020025274A patent/BR112020025274A8/en unknown
- 2019-06-20 MX MX2020013726A patent/MX2020013726A/en unknown
- 2019-06-20 WO PCT/US2019/038155 patent/WO2019246349A1/en unknown
- 2019-06-20 EA EA202190086A patent/EA202190086A1/en unknown
- 2019-06-21 AR ARP190101718A patent/AR115597A1/en unknown
-
2020
- 2020-12-10 IL IL279363A patent/IL279363A/en unknown
- 2020-12-14 NI NI202000101A patent/NI202000101A/en unknown
- 2020-12-16 PH PH12020552187A patent/PH12020552187A1/en unknown
- 2020-12-16 CL CL2020003257A patent/CL2020003257A1/en unknown
- 2020-12-17 DO DO2020000250A patent/DOP2020000250A/en unknown
-
2021
- 2021-01-18 EC ECSENADI20213643A patent/ECSP21003643A/en unknown
- 2021-01-19 CO CONC2021/0000456A patent/CO2021000456A2/en unknown
-
2022
- 2022-01-05 CL CL2022000027A patent/CL2022000027A1/en unknown
- 2022-06-30 US US17/854,379 patent/US20230159592A1/en active Pending
- 2022-07-22 JP JP2022117123A patent/JP2022141879A/en active Pending
- 2022-10-25 AU AU2022259744A patent/AU2022259744A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279363A (en) | Pcsk9 antagonist compounds | |
| PT3810602T (en) | Compounds | |
| GB201805174D0 (en) | Compounds | |
| GB201801355D0 (en) | Compounds | |
| EP3810129A4 (en) | Pcsk9 antagonist bicyclo-compounds | |
| GB201807924D0 (en) | Compounds | |
| EP4076492A4 (en) | Pcsk9 antagonist compounds | |
| IL277651A (en) | Ox2r compounds | |
| GB201817047D0 (en) | H4 antagonist compounds | |
| GB201808093D0 (en) | Compounds | |
| FI3810633T3 (en) | Compounds | |
| GB201810668D0 (en) | New compounds | |
| GB201809102D0 (en) | Compounds | |
| GB201811169D0 (en) | New compounds | |
| GB201810669D0 (en) | New compounds | |
| GB201803340D0 (en) | Compounds | |
| GB201801128D0 (en) | Compounds | |
| GB201801130D0 (en) | Compounds | |
| GB201812604D0 (en) | Antagonist compounds | |
| GB201910865D0 (en) | Antagonist compounds | |
| GB201904158D0 (en) | Antagonist compounds | |
| GB201910526D0 (en) | Antagonist | |
| GB201909500D0 (en) | Antagonist | |
| GB201817634D0 (en) | New compounds | |
| GB201813681D0 (en) | New compounds |